Newly emerging data support the link between autoimmunity and mental illnesses which has been examined since the 1930s, when a schizophrenia patient was tested positive for autoantibodies [1,2]. The thyroid is the most common organ affected by autoimmunity , with up to 5% of the general population suffering from autoimmune thyroid diseases . Thus, several studies have been conducted with the aim to discover whether there is a role for thyroid autoimmunity in psychiatric disorders. One of the main clinical manifestations of thyroid autoimmunity is Hashimoto’s thyroiditis (HT). Thyroid peroxidase antibodies (TPOAb) are considered to be the best serological marker of HT because about 95% of HT patients are TPOAb positive and false positive results are uncommon, whereas thyroglobulin antibodies (TGAb) are less sensitive and less specific compared with TPOAb . Thyroid sonogram results and a combination of clinical features are required along with antibody positivity for the diagnosis of HT, however, the prevalence of increased TPOAb titers with no clinical manifestation is high and may reach up to 15% among females [5,6]. In this review we focus on the association between thyroid autoimmunity (both HT and asymptomatic elevated TPOAb levels) and two major psychiatric conditions: depression and bipolar disorder.
2 Major depressive disorder
Major depressive disorder (MDD), also referred to as clinical depression, is diagnosed when a distinct change of mood characterized by sadness or irritability occurs for at least 2 weeks, interferes with work and family relations and is accompanied by several psychophysiological changes (e.g., disturbances of sleep and appetite; suicidal thoughts; slowing of speech and action) . MDD is associated with elevated risk of onset, persistence and severity of numerous secondary disorders (e.g., stroke, diabetes, coronary artery disease, certain types of cancer), increased suicide probability and many other issues (e.g., low education, marital disruption, unstable employment) . A cross-national comparison from population-based surveys in 10 countries concluded that the lifetime prevalence of MDD varies substantially across countries and ranges from 3.0% in Japan to 16.9% in the US . A specific form of MDD is postpartum depression (PPD) which is a major depressive episode with its onset within 4 weeks after delivery . The prevalence of PPD is 10-15 % in Western countries, but globally it ranges from almost 0% to nearly 60% . PPD affects not only the mother’s health, but also puts the offspring at risk by impairing their cognitive, social and emotional development .
In 1996 The World Health Organisation projected that by 2020 depression would be the second leading cause of disability worldwide , thereby encouraging further research concerning the causes of depression. However, due to the heterogeneity of MDD, its pathophysiology has been difficult to explain . Newly emerging data indicate that the immune system may be a potential factor contributing to the development of depression . Increased inflammatory cytokine levels in blood and cerebrospinal fluid as well as elevated acute phase protein concentrations in peripheral blood have been discovered in patients with MDD [16,17] and treatment with selective serotonin reuptake inhibitors has been reported to decrease serum levels of interleukin 6 . It is hypothesized that the dysfunction of the immune system may lead to the reduction of monoamine synaptic availability, which is considered a fundamental mechanism in the pathophysiology of depression . One of the first studies to show the connection between autoimmune thyroid disorders and depression was conducted in 1998 and included 583 perimenopausal women; after adjustment for psychosocial factors it was concluded that women with elevated TPOAb levels (≥100 IU/ml) are at risk for depression . Afterwards the association between MDD and thyroid autoimmunity was further examined in different studies; some of them aimed to reveal the link between HT and depression (see Table 1), while others focused on the connection between increased TPOAb levels and depressive symptoms among the general population (see Table 2).
The results of one study showed a higher prevalence of MDD among euthyroid HT patients and the findings of another one indicated that HT may increase the predisposition to depression [20,21]. Even though HT patients have been reported to be at higher risk for depression, l-thyroxine (T4) treatment for more than one year was found to reduce the chance of MDD . Robert Krysiak with colleagues  hypothesized that the development of depression in patients with HT may be linked to decreased sexual function. They observed more impaired sexual function among females with autoimmune subclinical hypothyroidism than among those with non-autoimmune subclinical hypothyroidism or euthyroid HT. Sexual dysfunction also correlated with the severity of depressive symptoms. It was concluded that both subclinical hypothyroidism and HT may have a negative effect on female sexual function and might contribute to the development of depressive symptoms . The study on males with autoimmune hypothyroidism led to the conclusion that even mild forms of autoimmune hypothyroidism are followed by sexual function impairment and depressive symptoms, both of them were reduced after T4 treatment .
Only one general population study showed a possible link between thyroid autoantibodies and depression (see Table 2): Itterman et al.  revealed that increased TPOAb levels were associated with MDD in the 12 months preceding the examination. However, that was not confirmed for TPOAb positivity (TPOAb+) and no connection was found between recurrent depression and TPOAb titer or TPOAb+. Thus, the authors concluded that it may be just a chance finding.
To our knowledge, a single study has provided an insight on the effect of thyroid autoimmunity on the response to antidepressants. In order to examine the connection, Eller and colleagues  compared the response to escitalopram treatment for MDD between TPOAb+ (>100 IU/ml) and TPOAb negative (TPOAb-) individuals. Although no significant differences were found, the non-responder group showed a trend for a higher prevalence of TPOAb+ compared with responders.
The findings of studies on TPOAb+ and PPD development are summarised in Table 3. Two of these studies identified an association between TPOAb+ during pregnancy and the development of PPD [29,30], while another one revealed that TPOAb values immediately after delivery do not affect PPD development . Thus, it might be concluded that the development of PPD is associated with TPOAb values during pregnancy, but not shortly after delivery.
3 Bipolar disorder
Bipolar disorder (BD) is a chronic, relapsing illness characterized by recurrent episodes of manic or depressive symptoms, with intervening relatively asymptomatic periods . The aggregate cross-study estimate of the lifetime prevalence of bipolar disorder is 1.2% , with a range of 0.1% in China , 1.0% in Germany  and up to 3.3% in the United States .
The interaction between genetic, environmental and psychosocial factors is believed to lead to the development of BD, but the exact cause remains unknown. Recent evidence suggests that the dysfunction of the immune system is linked to the pathophysiology of BD. A meta-analysis of 30 studies showed increased concentrations of proinflammatory cytokines among bipolar patients compared with healthy controls , another one also found some support for immune dysregulation in BD . This data leads to inquirer whether BD may be associated with organ-specific autoimmune disorders, including thyroid autoimmunity. The link between thyroid function and BD is usually explained by the use of lithium and its effect on the thyroid. For more than 60 years lithium has been the gold standard for BD treatment [39,40]. It is now known that lithium definitely affects thyroid function , probably by inhibiting T3 and T4 release , but the exact mechanism remains elusive. During the first years of treatment, the patients are more prone to develop hypothyroidism, whereas hyperthyroidism and thyroid cancer are uncommon . The association between lithium treatment and thyroid autoimmunity has been studied, but the question whether lithium per se can induce an increase in anti-thyroid antibody titers remains open to discussion . Thyroid autoimmunity has been found to be more prevalent among BD affected individuals, irrespective of treatment. In 2002, Kupka with colleagues  reported that 28% of their studied bipolar patients were positive for TPOAb (≥10IU/ml), compared with 3-18% for population and psychiatric controls; this increased prevalence was not associated with lithium treatment. Afterwards a group of researchers conducted three consecutive studies and concluded that their findings point to a possible increased inherited risk of the co-occurrence of BD and AIT [45, 46, 47]. However, their results were contradictory to the ones of another study which showed no familial association between BD and thyroid autoimmunity  (see Table 4).
The results of most studies point towards the conclusion that thyroid autoimmunity is associated with both MDD and BD. Euthyroid HT patients have been shown to be more prone to depression, thus, MDD may be linked to the presence of high TPOAb titers among HT patients irrespective of their thyroid function. However, current data show no link between slightly elevated TPOAb levels and depressive symptoms among the general population. TPOAb+ during pregnancy has been linked to PPD development, but the presence of TPOAb shortly after delivery has not been found to be associated with PPD. In addition, further research is needed to assess the effect of TPOAb+ on the response to antidepressants.
Unfortunately, the association between BD and thyroid autoimmunity still remains unclear. The offspring of bipolar parents have shown higher rates of TPOAb+ and the twin study has led to the theory that BD and thyroid autoimmunity may be a result of the same genetic disturbance, but other scientists report to have found no association between BD and TPOAb levels. Thus, further large-scale research is needed to reach final conclusions.
- T4: l-
major depressive disorder
Thyroid peroxidase antibodies
thyroid peroxidase antibody negativity
thyroid peroxidase antibody positivity
Kayser MS, Dalmau J. The emerging link between autoimmune disorders and neuropsychiatric disease. J Neuropsychiatry Clin Neurosci 2011;23:90-97. doi:10.1176/jnp.23.1.jnp90 CrossrefPubMedWeb of ScienceGoogle Scholar
Andrade L, Caraveo-Anduaga JJ, Berglund P, Bijl RV., De Graaf R, Vollebergh W, et al. The epidemiology of major depressive episodes: Results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res 2003;12:3-21. doi:10.1002/mpr.138 PubMedCrossrefGoogle Scholar
Halbreich U, Karkun S. Cross-cultural and social diversity of prevalence of postpartum depression and depressive symptoms. J Affect Disord 2006;91:97-111. doi:10.1016/j. jad.2005.12.051 PubMedCrossrefGoogle Scholar
Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol 2015;16:22-34. doi:10.1038/nri.2015.5 Web of ScienceGoogle Scholar
Zorrilla EP, Luborsky L, McKay JR, Rosenthal R, Houldin A, Tax A, et al. The Relationship of Depression and Stressors to Immunological Assays: A Meta-Analytic Review. Brain Behav Immun 2001;15:199-226. doi:10.1006/brbi.2000.0597 PubMedCrossrefGoogle Scholar
Basterzi AD, Aydemir Ç, Kisa C, Aksaray S, Tuzer V, Yazici K, et al. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum Psychopharmacol 2005;20:473-476. doi:10.1002/hup.717 PubMedCrossrefGoogle Scholar
Pop VJ, Maartens LH, Leusink G, van Son MJ, Knottnerus AA, Ward AM, et al. Are Autoimmune Thyroid Dysfunction and Depression Related? J Clin Endocrinol Metab 1998;83:3194-3197. doi:10.1210/jcem.83.9.5131 PubMedGoogle Scholar
Giynas Ayhan M, Uguz F, Askin R, Gonen MS. The prevalence of depression and anxiety disorders in patients with euthyroid Hashimoto’s thyroiditis: A comparative study. Gen Hosp Psychiatry 2014;36:95-98. doi:10.1016/j. genhosppsych.2013.10.002 PubMedCrossrefWeb of ScienceGoogle Scholar
Yalcin MM, Altinova AE, Cavnar B, Bolayir B, Akturk M, Arslan E, et al. Is thyroid autoimmunity itself associated with psychological well-being in euthyroid Hashimoto’s thyroiditis? Endocr J 2017;64:425-429. doi:10.1507/endocrj. EJ16-0418 PubMedCrossrefWeb of ScienceGoogle Scholar
Lin I-C, Chen H-H, Yeh S-Y, Lin C-L, Kao C-H. Risk of Depression, Chronic Morbidities, and l-Thyroxine Treatment in Hashimoto Thyroiditis in Taiwan. Medicine (Baltimore) 2016;95:e2842. doi:10.1097/MD.0000000000002842 CrossrefWeb of SciencePubMedGoogle Scholar
Krysiak R, Drosdzol-Cop A, Skrzypulec-Plinta V, Okopien B. Sexual function and depressive symptoms in young women with thyroid autoimmunity and subclinical hypothyroidism. Clin Endocrinol (Oxf) 2016;84:925-931. doi:10.1111/cen.12956 PubMedCrossrefGoogle Scholar
Krysiak R, Szkrobka W, Okopien B. The effect of L-thyroxine treatment on sexual function and depressive symptoms in men with autoimmune hypothyroidism. Pharmacol Reports 2017;69:432-437. doi:10.1016/j.pharep.2017.01.005 CrossrefWeb of ScienceGoogle Scholar
Ittermann T, Völzke H, Baumeister SE, Appel K, Grabe HJ. Diagnosed thyroid disorders are associated with depression and anxiety. Soc Psychiatry Psychiatr Epidemiol 2015;50:1417-1425. doi:10.1007/s00127-015-1043-0 PubMedCrossrefWeb of ScienceGoogle Scholar
Delitala AP, Terracciano A, Fiorillo E, Orru V, Schlessinger D, Cucca F. Depressive symptoms, thyroid hormone and autoimmunity in a population-based cohort from Sardinia. J Affect Disord 2016;191:82-87. doi:10.1016/j.jad.2015.11.019 CrossrefWeb of ScienceGoogle Scholar
Medici M, Direk N, Visser WE, Korevaar TIM, Hofman A, Visser TJ, et al. Thyroid Function Within the Normal Range and the Risk of Depression: A Population-Based Cohort Study. J Clin Endocrinol Metab 2014;99:1213-1219. doi:10.1210/jc.2013-3589 PubMedCrossrefWeb of ScienceGoogle Scholar
Eller T, Metsküla K, Talja I, Maron E, Uibo R, Vasar V. Thyroid autoimmunity and treatment response to escitalopram in major depression. Nord J Psychiatry 2010;64:253–7. doi:10.3109/08039480903487533 Web of ScienceCrossrefPubMedGoogle Scholar
Kuijpens JL, Vader HL, Drexhage HA, Wiersinga WM, Van Son MJ, Pop VJ. Thyroid peroxidase antibodies during gestation are a marker for subsequent depression postpartum. Eur J Endocrinol 2001;145:579-584. doi:10.1530/eje.0.1450579 PubMedGoogle Scholar
Groer MW, Vaughan JH. Positive Thyroid Peroxidase Antibody Titer is Associated with Dysphoric Moods during Pregnancy and Postpartum. JOGNN - J Obstet Gynecol Neonatal Nurs 2013;42:E26-32. doi:10.1038/jid.2014.371 CrossrefGoogle Scholar
Albacar G, Sans T, Martín-Santos R, García-Esteve L, Guillamat R, Sanjuan J, et al. Thyroid function 48h after delivery as a marker for subsequent postpartum depression. Psychoneuroendocrinology 2010;35:738-742. doi:10.1016/j. psyneuen.2009.10.015 PubMedCrossrefGoogle Scholar
Jann MW. Diagnosis and treatment of bipolar disorders in adults: A review of the evidence on pharmacologic treatments. Am Heal Drug Benefits 2014;7:489-499 Google Scholar
Merikangas KR, Pato M. Recent Developments in the Epidemiology of Bipolar Disorder in Adults and Children : Magnitude, Correlates, and Future Directions. Clin Psychol Sci Pract 2009;16:121-133. doi:10.1111/j.1468-2850.2009.01152.x Web of ScienceCrossrefGoogle Scholar
Lee S, Tsang A, Zhang M-Y, Huang Y-Q, He Y-L, Liu Z-R, et al. Lifetime Prevalence and Inter-cohort Variation in DSM-IV Disorders in Metropolitan China. Psychol Med 2007;37:61-71. doi:10.1038/jid.2014.371 Web of SciencePubMedCrossrefGoogle Scholar
Jacobi F, Wittchen H-U, Holting C, Hofler M, Pfister H, Muller N, et al. Prevalence, co-morbidity and correlates of mental disorders in the general population: results from the German Health Interview and Examination Survey (GHS). Psychol Med 2004;34:597-611. doi:10.1017/S0033291703001399 CrossrefPubMedGoogle Scholar
Grant BF, Stinson FS, Hasin DS, Dawson DA, Chou SP, Ruan WJ, et al. Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2005;66:1205-1215. doi:16259532 CrossrefPubMedGoogle Scholar
Modabbernia A, Taslimi S, Brietzke E, Ashrafi M. Cytokine alterations in bipolar disorder: A meta-analysis of 30 studies. Biol Psychiatry 2013;74:15-25. doi:10.1016/j. biopsych.2013.01.007 CrossrefWeb of SciencePubMedGoogle Scholar
Munkholm K, Vinberg M, Vedel Kessing L. Cytokines in bipolar disorder: A systematic review and meta-analysis. J Affect Disord 2013;144:16-27. doi:10.1016/j.jad.2012.06.010 CrossrefWeb of SciencePubMedGoogle Scholar
Machado-Vieira R, Manji HK, Zarate CA. The role of lithium in the treatment of bipolar disorder: Convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord 2009;11:92-109. doi:10.1111/j.1399-5618.2009.00714.x PubMedCrossrefWeb of ScienceGoogle Scholar
Girardi P, Brugnoli R, Manfredi G, Sani G. Lithium in Bipolar Disorder: Optimizing Therapy Using Prolonged-Release Formulations. Drugs R D 2016;16:293–302. doi:10.1007/s40268-016-0139-7 CrossrefWeb of SciencePubMedGoogle Scholar
Mori M, Tajima K, Oda Y, Matsui I, Mashita K, Tarui S. Inhibitory effect of lithium on the release of thyroid hormones from thyrotropin-stimulated mouse thyroids in a perifusion system. Endocrinology 1989;124:1365-1369. doi:10.1210/endo-124-3-1365 CrossrefGoogle Scholar
Kupka RW, Nolen WA, Post RM, McElroy SL, Altshuler LL, Denicoff KD, et al. High rate of autoimmune thyroiditis in bipolar disorder: Lack of association with lithium exposure. Biol Psychiatry 2002;51:305-311. doi:10.1016/S0006-3223(01)01217-3 PubMedCrossrefGoogle Scholar
Hillegers MHJ, Reichart CG, Wals M, Verhulst FC, Ormel J, Nolen WA, et al. Signs of a higher prevalence of autoimmune thyroiditis in female offspring of bipolar parents. Eur Neuropsychopharmacol 2007;17:394-399. doi:10.1016/j. euroneuro.2006.10.005 Web of ScienceCrossrefPubMedGoogle Scholar
Vonk R, van der Schot AC, Kahn RS, Nolen WA, Drexhage HA. Is Autoimmune Thyroiditis Part of the Genetic Vulnerability (or an Endophenotype) for Bipolar Disorder? Biol Psychiatry 2007;62:135-140. doi:10.1016/j.biopsych.2006.08.041 Web of ScienceCrossrefGoogle Scholar
Snijders G, De Witte L, Mesman E, Kemner S, Vonk R, Brouwer R, et al. The seroprevalence of antithyroid peroxidase antibodies in bipolar families and bipolar twins: results from two longitudinal studies. Int J Bipolar Disord 2017;5:1. doi:10.1186/s40345-017-0070-z Web of SciencePubMedCrossrefGoogle Scholar
Cobo J, Giménez-Palop O, Patró E, Pérez M, Bleda F, Barbero JD, et al. Lack of confirmation of thyroid endophenotype in Bipolar Disorder Type I and their first-degree relatives. Psychoneuroendocrinology 2015;51:351-364. doi:10.1016/j. psyneuen.2014.09.032 PubMedWeb of ScienceCrossrefGoogle Scholar
About the article
Published Online: 2019-01-16
Conflict of interestConflict of interest statement: Authors state no conflict of interest.
Citation Information: Open Medicine, Volume 14, Issue 1, Pages 52–58, ISSN (Online) 2391-5463, DOI: https://doi.org/10.1515/med-2019-0008.
© 2019 Neringa Jucevičiūtė et al., published by De Gruyter. This work is licensed under the Creative Commons Attribution 4.0 Public License. BY 4.0